Melanoma Surgery »  Faculty »  Medical Oncology »  Adil I. Daud, M.D.
 
General Surgery Programs
Department of Surgery Websites

Make a Gift

A gift to the Melanoma Program helps our physicians and scientists discover new
treatments and cures related to skin cancer.

 

How you can help »
Melanoma Surgery »  Faculty »  Medical Oncology »  Adil I. Daud, M.D.

Adil I. Daud, M.D.

Health Sciences Clinical Professor of Medicine
Department of Medicine
Division of Hematology/Oncology
Co-Director, UCSF Melanoma Center
Director, Melanoma Clinical Research,
UCSF Helen Diller Family Comprehensive Cancer Center

Contact Information

Academic Office
Telephone: 415-353-7392
Fax: 415-353-9956
adaud@medicine.ucsf.edu		 Clinic Appointments
Melanoma Center
1600 Divisadero St., Fourth Floor
San Francisco, CA 94115
Phone: (415) 353-9900
Fax: (415) 885-3802

Education

  • St. Francis De Sales College, Nagpur, India, 1980, HSC Diploma in General Science
  • Government Medical College, Nagpur, India, 1986, MBBS degree in Medicine

Residencies

  • Internship and Residency in Internal Medicine, Indiana University Medical Center, Indianapolis, IN, 1994-1997

Fellowships

  • Fellowship in Hematology/Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, 1997-2000

Postdoctoral Training

  • Postdoctoral Fellow, Laboratory of F. Merlin Bumpus, PhD and Ahsan Husain, PhD, Cleveland Clinic Foundation, Cleveland, OH, 1987-1990
  • Research Assistant Staff, Laboratory of Loren Field, PhD, Krannert Institute of Cardiology, Indiana University Medical Center, Indianapolis, IN, 1990-1994

Board Certification

  • American Board of Internal Medicine, Internal Medicine
  • American Board of Internal Medicine, Hematology
  • American Board of Internal Medicine, Medical Oncology

Program Affiliations

  • Department of Medicine, Division of Hematology Oncology
  • Member, UCSF Helen Diller Family Comprehensive Cancer Center
  • UCSF Melanoma Center

Clinical Expertise

  • Basal Cell Carcinoma
  • Kaposi's sarcoma
  • Melanoma
  • Merkel Cell Carcinoma
  • Skin adnexal tumors
  • Skin Cancer in Immunosuppressed Patients
  • Skin sarcomas
  • Squamous Cell Carcinoma

Research Interests

  • BRAF Mutation-Positive Metastatic Melanoma
  • Phase I Investigational Agents for Solid Tumors
  • Targeted Therapy in Melanoma

Biography

Dr Adil Daud is a nationally recognized expert in early phase drug development in skin cancer and solid tumors. He earned a medical degree at the Government Medical College in Nagpur, India. He completed an internship and residency in internal medicine at Indiana University Medical Center, followed by a fellowship in hematology-oncology at Memorial Sloan-Kettering Cancer Center.

Prior to joining UCSF Medical Center, he was Associate Professor and Director of the Affiliate Network at the Moffitt Cancer Center in Tampa, Fla. for seven years. Daud has won numerous awards, including the American Society for Clinical Oncology's Young Investigator award and Castle Connolly's Best Doctors in America award. He is an professor of medicine at UCSF.

Research Summary

Dr. Daud is Director of Melanoma Research at the UCSF Helen Diller Family Comprehensive Cancer Center. The programs goal is to better understand the biology of melanoma and develop new treatments for the disease. Daud has led numerous clinical trials that have expanded the use of targeted therapy for melanoma.

Selected Publications

  1. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma.
    Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R J Clin Oncol. 2008 December 20; 26(36): 5896-5903.
  2. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor.
    Daud AI, Mirza N, Lenox B, Andrews S, Urbas P, Gao GX, Lee JH, Sondak VK, Riker AI, Deconti RC, Gabrilovich D. J Clin Oncol. 2008 Jul 1;26(19):3235-41.
  3. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
    Daud AI, Dawson J, DeConti RC, Bicaku E, Marchion D, Bastien S, Hausheer FA 3rd, Lush R, Neuger A, Sullivan DM, Munster PN., Clin Cancer Res. 2009 Apr 1;15(7):2479-87. Epub 2009 Mar 24.
  4. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. Münster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D, Daud A., J Clin Oncol. 2007 May 20;25(15):1979-85
  5. Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study.
    Daud A, Valkov N, Centeno B, Derderian J, Sullivan P, Munster P, Urbas P, Deconti RC, Berghorn E, Liu Z, Hausheer F, Sullivan D., Clin Cancer Res. 2005 Apr 15;11(8):3009-16
View All Publications at UCSF Profiles (Powered by CTSI)

X